Veradermics is trading at $114.08, down 4.03%, with biotech-sector weakness the best available explanation, though no company-specific catalyst was identified.
- Biotech ETF XBI fell 2.50% during the regular session.
- No clear Veradermics-specific announcement for October 6 was identified; the latest company-specific clinical news predates the move.
- The broader market was positive; intraday volume or activity data was unavailable.